

ForPatients

by Roche

Breast Cancer

A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03558490 ML39208

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a three-month open-label, multicenter, interventional, single arm study located in France, designed to assess feasibility and reliability of the e-Health ZEMY software medical device under investigation for use by participants with breast cancer, who are starting an anti-cancer treatment at any stage of the disease, to manage disease symptoms and anti-cancer treatment-related toxicities while at home.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03558490 ML39208
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
>= 18 Years

Healthy Volunteers
No
